Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Polycystic Ovary Syndrome 7Neoplasms 6Breast Neoplasms 6Vomiting 2Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Melanoma 2Diabetes Mellitus 2Weight Gain 1Venous Thromboembolism 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Renal Insufficiency 1Prostatic Neoplasms 1Primary Myelofibrosis 1Premature Birth 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-Eclampsia 1Polycythemia Vera 1Parathyroid Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Nausea 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 33pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × Tablets × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00667485 2014-01-17

Rapamycin Plus Bevacizumab in Advanced Cancers

University of Chicago

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡